Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

HANSOH Aktie

 >HANSOH Aktienkurs 
3.06 EUR    (Tradegate)
Ask: 3.08 EUR / 961 Stück
Bid: 3.04 EUR / 980 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
HANSOH Aktie über LYNX handeln
>HANSOH Performance
1 Woche: -3,2%
1 Monat: +7,7%
3 Monate: +21,4%
6 Monate: +39,1%
1 Jahr: +54,9%
laufendes Jahr: +43,0%
>HANSOH Aktie
Name:  HANSOH PHARMACEUTICAL GROUP
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG549581067 / A2PLRC
Symbol/ Ticker:  3KY (Frankfurt)
Kürzel:  FRA:3KY, ETR:3KY, 3KY:GR
Index:  -
Webseite:  https://www.hansoh.cn/en/
Marktkapitalisierung:  19200 Mio. EUR
Umsatz:  10614.63 Mio. EUR
EBITDA:  3705.6 Mio. EUR
Gewinn je Aktie:  0.078 EUR
Schulden:  102.07 Mio. EUR
Liquide Mittel:  20276.88 Mio. EUR
Umsatz-/ Gewinnwachstum:  2.9% / -17.2%
KGV/ KGV lG:  36.81 / 37.45
KUV/ KBV/ PEG:  13.04 / 5.57 / -
Gewinnm./ Eigenkapitalr.:  35.66% / 16.05%
Dividende je Aktie:  0.04 EUR
Dividendenrendite/ -schätzung:  1.2% / 0.99%
Div. Historie:  20.09.24 - 0.02311€
19.06.24 - 0.01696€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  HANSOH
Letzte Datenerhebung:  22.06.25
>HANSOH Eigentümer
Aktien: 5950 Mio. St.
f.h. Aktien: 1120 Mio. St.
Insider Eigner: 81.11%
Instit. Eigner: 9.51%
Leerverk. Aktien: -
>HANSOH Peer Group

 
19.06.25 - 07:15
Research: UOB Kay Hian: Industry Enters New Phase of Accelerated Growth; Top Picks INNOVENT BIO/ HANSOH PHARMA/ SINO BIOPHARM (AAStocks)
 
The Chinese biotech industry entered a phase of accelerated growth, with companies expanding their innovative commercial product portfolios, nailing major out-licensing deals, and exceeding expected profitability, UOB Kay Hian's research report said.Ongoing policy support and globalization efforts will further foster the ind......
12.06.25 - 10:15
Full-day Takeaway: HSI Down 331 pts; HSTI Down 119 pts; BABA Down over 3%; SINO BIOPHARM, ZIJIN MINING, WUXI APPTEC, HANSOH PHARMA, CHOW TAI FOOK Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI dropped 331 pts or 1.4% to 24,035. HSTI dropped 119 pts or 2.2% to 5,331. HSCEI fell 135 pts or 1.5% to 8,729. Market turnover reached $244.41 billion.Active Heavyweights:BABA (09988.HK) closed at $114.6, down 3.2%HKEX (00388.HK) closed at $411.4, down 2.1%MEITUAN (03690.HK) closed at $141, down 1.9%AIA (01299.HK) ......
12.06.25 - 06:15
Midday Takeaway: HSI Closes Midday at 24,244, Down 121 pts; HSTI Closes Midday at 5,393, Down 57 pts; SINO BIOPHARM Up over 15%; CCB, SINO BIOPHARM, ZIJIN MINING, WUXI APPTEC, HANSOH PHARMA Hit New Highs (AAStocks)
 
At midday close, HSI dropped 121 pts or 0.5% to 24,244. HSTI dropped 57 pts or 1.1% to 5,393. HSCEI fell 45 pts or 0.5% to 8,820.Active Heavyweights:BABA (09988.HK) closed at $116, down 2%HKEX (00388.HK) closed at $417, down 0.8%CCB (00939.HK) closed at $7.71, up 0.8%, hitting new highPING AN (02318.HK) closed at $49.05, up 0.6%......
11.06.25 - 05:45
Research: UBS Raises HANSOH PHARMA TP to $33.3, Reiterates Rating at Buy (AAStocks)
 
UBS issued a research report believing that HANSOH PHARMA (03692.HK)'s share price is still undervalued, even after a 53% rally YTD.UBS raised its 2025-2027 EPS forecasts for HANSOH PHARMA by 16.2%/ 17.7%/ 21.3% each, and its revenue forecasts by 6-12%. The broker expected Aumolertinib and business development (BD) to be the......
10.06.25 - 10:15
Full-day Takeaway: HSI Closes at 24,162, Down 18 pts; HSTI Closes at 5,392, Down 41 pts; CHINAHONGQIAO Up over 4%; CCB, HANSOH PHARMA, CSPC PHARMA, ABC, CHINA RES MIXC Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI dropped 18 pts or 0.1% to 24,162. HSTI dropped 41 pts or 0.8% to 5,392. HSCEI fell 12 pts or 0.1% to 8,767. Market turnover reached $250.34 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $144.4, down 2.7%AIA (01299.HK) closed at $69.7, up 1.1%TENCENT (00700.HK) closed at $513.5, down 0.9%CCB (00939.HK) cl......
10.06.25 - 06:15
Midday Takeaway: HSI Closes Midday at 24,261, Up 79 pts; HSTI Closes Midday at 5,415, Down 17 pts; CSPC PHARMA Up over 5%; CCB, CSPC PHARMA, HANSOH PHARMA, CHINA RES MIXC, ICBC Hit New Highs (AAStocks)
 
At midday close, HSI rose 79 pts or 0.3% to 24,261. HSTI dropped 17 pts or 0.3% to 5,415. HSCEI gained 29 pts or 0.3% to 8,809.Active Heavyweights:MEITUAN (03690.HK) closed at $146.2, down 1.5%PING AN (02318.HK) closed at $47.85, up 1.4%CCB (00939.HK) closed at $7.5, up 0.8%, hitting new highTENCENT (00700.HK) closed at $515.5, ......
10.06.25 - 05:30
Research: HSBC Research Expects CN Pharma Firms to Benefit from Biz Development, Prefers HENGRUI PHARMA/ HANSOH PHARMA (AAStocks)
 
China's pharmaceutical sector outperformed the market YTD, but performance of key 'cash cow' products is expected to continue to decline due to medical insurance pressures, according to a research report issued by HSBC Global Research. Nevertheless, the broker estimated encouraging results from early-stage assets of ......
09.06.25 - 10:30
Full-day Takeaway: HSI Up 388 pts; HSTI Up 146 pts; MEITUAN Up over 4%; HKEX Up over 3%; PING AN Up over 3%; HKEX, CCB, NTES, HANSOH PHARMA, HANG SENG BANK Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 388 pts or 1.6% to 24,181. HSTI rose 146 pts or 2.8% to 5,433. HSCEI gained 150 pts or 1.7% to 8,780. Market turnover reached $245.83 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $148.4, up 4.7%HKEX (00388.HK) closed at $415.8, up 3.3%, hitting new highPING AN (02318.HK) closed at $47.2, up 3.3%AIA......
05.06.25 - 16:00
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock? (Zacks)
 
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks....
05.06.25 - 07:15
Research: UOB Kay Hian Lifts HANSOH PHARMA's TP to HKD40 w/ Buy Rating (AAStocks)
 
According to a report issued by UOB Kay Hian, HANSOH PHARMA (03692.HK) has received approval for two new indications for Ameile and market approval for NSCLC indication in the UK.Meanwhile, HANSOH PHARMA's Hengmeida, which is used for the treatment of candidiasis, has been granted a drug registration certificate by China'......
04.06.25 - 10:15
Full-day Takeaway: HSI Closes at 23,654, Up 141 pts; HSTI Closes at 5,219, Up 29 pts; MEITUAN Up over 3%; HKEX, CCB, SINO BIOPHARM, HANSOH PHARMA, ABC Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 141 pts or 0.6% to 23,654. HSTI rose 29 pts or 0.6% to 5,219. HSCEI gained 56 pts or 0.7% to 8,576. Market turnover reached $212.69 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $140.7, up 3%HKEX (00388.HK) closed at $403, up 1.9%, hitting new highAIA (01299.HK) closed at $66.05, down 1.4%PING AN (0......
04.06.25 - 06:15
Midday Takeaway: HSI Closes Midday at 23,680, Up 168 pts; HSTI Closes Midday at 5,241, Up 52 pts; MEITUAN Up over 4%; HKEX, SINO BIOPHARM, HANSOH PHARMA, CHOW TAI FOOK, ABC Hit New Highs (AAStocks)
 
At midday close, HSI rose 168 pts or 0.7% to 23,680. HSTI rose 52 pts or 1.0% to 5,241. HSCEI gained 74 pts or 0.9% to 8,594.Active Heavyweights:MEITUAN (03690.HK) closed at $142.2, up 4.1%HKEX (00388.HK) closed at $402.8, up 1.9%, hitting new highPING AN (02318.HK) closed at $45.8, down 1.4%BABA (09988.HK) closed at $115.4, up ......
03.06.25 - 04:30
Research: Nomura Lifts HANSOH PHARMAs TP to HKD25.64 on Product Licensing (AAStocks)
 
HANSOH PHARMA (03692.HK) announced a collaboration with Regeneron (REGN.US), under which HANSOH PHARMA will grant Regeneron an exclusive worldwide (excluding Mainland China, Hong Kong, and Macau) license to develop, manufacture, and commercialize HS-20094. In return, HANSOH PHARMA will receive an upfront payment of USD80 million......
03.06.25 - 04:00
HANSOH PHARMA Opens Up ~4%; Upfront Payment USD80M Received After Granting Product License to Regeneron (AAStocks)
 
Blue-chip pharma stock HANSOH PHARMA (03692.HK) opened 3.85% higher today (3rd). It last traded at HKD27, up 3.85%, on a pre-market volume of 70,700 shares, involving HKD1.9083 million.The group announced after market close yesterday (2nd) that it has granted Regeneron (REGN.US) an exclusive worldwide license (excluding Mainland......
02.06.25 - 13:48
Regeneron Enters In-licensing Agreement With Hansoh Pharma For HS-20094 (AFX)
 
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced an in-licensing agreement with Hansoh Pharmaceuticals to acquire clinical development and commercial rights outside of the Chinese......
02.06.25 - 13:09
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist (GlobeNewswire EN)
 
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China...
27.05.25 - 10:15
Full-day Takeaway: HSI Closes at 23,381, Up 99 pts; HSTI Closes at 5,182, Up 24 pts; CSPC PHARMA Up over 5%; HANSOH PHARMA, CHINA MOBILE, SIMCERE PHARMA, CHINA EAST EDU, SINOFERT Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 99 pts or 0.4% to 23,381. HSTI rose 24 pts or 0.5% to 5,182. HSCEI gained 32 pts or 0.4% to 8,469. Market turnover reached $203.27 billion.Active Heavyweights:HKEX (00388.HK) closed at $398.2, up 2.8%MEITUAN (03690.HK) closed at $132.1, up 2.1%AIA (01299.HK) closed at $65.2, up 1.2%BABA (09988.HK) closed at $1......
20.05.25 - 06:30
Midday Takeaway: HSI Up 301 pts; HSTI Up 69 pts; HANSOH PHARMA Up over 9%; SINO BIOPHARM, BYD COMPANY, BOC HONG KONG, CHINA MOBILE, 3SBIO Hit New Highs (AAStocks)
 
At midday close, HSI rose 301 pts or 1.3% to 23,634. HSTI rose 69 pts or 1.3% to 5,324. HSCEI gained 110 pts or 1.3% to 8,570.Active Heavyweights:BABA (09988.HK) closed at $122.2, up 2.5%AIA (01299.HK) closed at $67.25, up 2.5%MEITUAN (03690.HK) closed at $135.4, up 0.7%CCB (00939.HK) closed at $6.9, up 0.7%HKEX (00388.HK) close......
19.05.25 - 05:45
Research: M Stanley Bullish on CN Pharma Sector, Raising TPs for HANSOH PHARMA, Others (AAStocks)
 
Morgan Stanley has issued a research report expressing an optimistic outlook for China's pharma industry in light of a series of favorable domestic policies like comprehensive support for innovation.In addition, most Chinese pharma companies have low reliance on exports to the US, making the sector relatively less vulnerable......
13.05.25 - 06:00
Research: CLSA Adds Basket Allocation on CSPC PHARMA/ HANSOH PHARMA/ Hengrui as CN Policy Environment Now More Supportive for Pharmas (AAStocks)
 
CLSA opined in its research report that comments from US President Donald Trump regarding drug pricing had reignited market volatility.In CLSA's opinion, the multi-payer structure of the US healthcare system limits the government's power to set prices, and any meaningful reform would impact a wide range of stakeholders, ......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein dummer Bodybuilder redet Maskulatur. - Dr. Fritz P. Rinnhofer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!